SLRN Quote, Financials, Valuation and Earnings

Alumis has a net margin of -- compared to Acelyrin's net margin of --. Acelyrin's return on equity of -- beat Alumis's return on equity of --.

Acelyrin has a consensus price target of $8.00, signalling upside risk potential of 268.66%. On the other hand Alumis has an analysts' consensus of $21.50 which suggests that it could grow by 402.34%. Given that Alumis has higher upside potential than Acelyrin, analysts believe Alumis is more attractive than Acelyrin.

Acelyrin has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alumis has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Acelyrin has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alumis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acelyrin pays -- of its earnings as a dividend. Alumis pays out -- of its earnings as a dividend.

Acelyrin quarterly revenues are --, which are smaller than Alumis quarterly revenues of --. Acelyrin's net income of -$79M is higher than Alumis's net income of -$94.8M. Notably, Acelyrin's price-to-earnings ratio is -- while Alumis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acelyrin is -- versus -- for Alumis. Usually stocks with elevated PS ratios are considered overvalued.

OptiNose has a net margin of -- compared to Acelyrin's net margin of -1.61%. Acelyrin's return on equity of -- beat OptiNose's return on equity of --.

Acelyrin has a consensus price target of $8.00, signalling upside risk potential of 268.66%. On the other hand OptiNose has an analysts' consensus of $18.00 which suggests that it could grow by 93.97%. Given that Acelyrin has higher upside potential than OptiNose, analysts believe Acelyrin is more attractive than OptiNose.

Acelyrin has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OptiNose has a beta of -0.873, suggesting its less volatile than the S&P 500 by 187.316%.

Acelyrin has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptiNose offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acelyrin pays -- of its earnings as a dividend. OptiNose pays out -- of its earnings as a dividend.

Acelyrin quarterly revenues are --, which are smaller than OptiNose quarterly revenues of $22.4M. Acelyrin's net income of -$79M is lower than OptiNose's net income of -$360K. Notably, Acelyrin's price-to-earnings ratio is -- while OptiNose's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acelyrin is -- versus 1.21x for OptiNose. Usually stocks with elevated PS ratios are considered overvalued.

Pliant Therapeutics has a net margin of -- compared to Acelyrin's net margin of --. Acelyrin's return on equity of -- beat Pliant Therapeutics's return on equity of --.

Acelyrin has a consensus price target of $8.00, signalling upside risk potential of 268.66%. On the other hand Pliant Therapeutics has an analysts' consensus of $10.06 which suggests that it could grow by 589.21%. Given that Pliant Therapeutics has higher upside potential than Acelyrin, analysts believe Pliant Therapeutics is more attractive than Acelyrin.

Acelyrin has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pliant Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Acelyrin has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pliant Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acelyrin pays -- of its earnings as a dividend. Pliant Therapeutics pays out -- of its earnings as a dividend.

Acelyrin quarterly revenues are --, which are smaller than Pliant Therapeutics quarterly revenues of --. Acelyrin's net income of -$79M is lower than Pliant Therapeutics's net income of -$49.7M. Notably, Acelyrin's price-to-earnings ratio is -- while Pliant Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acelyrin is -- versus 17.58x for Pliant Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -- compared to Acelyrin's net margin of -489.18%. Acelyrin's return on equity of -- beat Sutro Biopharma's return on equity of -204.67%.

Acelyrin has a consensus price target of $8.00, signalling upside risk potential of 268.66%. On the other hand Sutro Biopharma has an analysts' consensus of $3.43 which suggests that it could grow by 279.86%. Given that Sutro Biopharma has higher upside potential than Acelyrin, analysts believe Sutro Biopharma is more attractive than Acelyrin.

Acelyrin has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.657%.

Acelyrin has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acelyrin pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Acelyrin quarterly revenues are --, which are smaller than Sutro Biopharma quarterly revenues of $14.8M. Acelyrin's net income of -$79M is lower than Sutro Biopharma's net income of -$72.4M. Notably, Acelyrin's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acelyrin is -- versus 1.12x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.